☆ 4.6 Article

Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series

INFECTION AND DRUG RESISTANCE (2023)

Related references

Note: Only part of the references are listed.

Review Dermatology

Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors

Kaitlynne N. Cunningham et al.

Summary: Vitiligo is a chronic autoimmune disease causing loss of skin pigmentation, affecting 0.5-2% of the global population. Significant progress has been made in understanding the pathogenesis of vitiligo, which involves a combination of genetics, oxidative stress, inflammation, and environmental triggers. Conventional treatments include camouflage, topical corticosteroids, oral corticosteroids, phototherapy, and surgery, but a new cream targeting the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway has recently been approved by the US FDA for repigmentation in vitiligo patients.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2023)

Add to Collection

Review Allergy

Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors

Chisa Nakashima et al.

Summary: Atopic dermatitis is a chronic, eczematous skin condition characterized by severe itchiness. Th2 cell-mediated immunity, skin barrier dysfunction, and pruritus contribute to the development of atopic dermatitis. The JAK/STAT pathway is involved in various inflammatory diseases, including atopic dermatitis. JAK inhibitors show promise as potential treatments for severe atopic dermatitis.

ALLERGOLOGY INTERNATIONAL (2022)

Add to Collection

Article Dermatology

Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real-world clinical practice

Hongbin Song et al.

Summary: This study evaluated the efficacy and safety of tofacitinib combined with narrowband ultraviolet B (NB-UVB) phototherapy for refractory nonsegmental vitiligo. The results showed that the combination group had significantly higher levels of repigmentation and response rate compared to the control group. Tofacitinib combined with NB-UVB phototherapy may be an effective and safe alternative treatment for refractory vitiligo.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Review Immunology

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata

Maddison Lensing et al.

Summary: Alopecia Areata (AA) is a common autoimmune disease characterized by hair loss. The breakdown of immune privilege of the hair follicle plays a role in the development of the disease. IFN gamma and other cytokines are involved in the pathogenesis of AA. Targeting the JAK/STAT signaling pathways has been shown to be effective in treating the disease.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Dermatology

Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study

Ulrich Mrowietz et al.

Summary: Palmoplantar pustulosis (PPP) is a chronic, inflammatory skin disease with high disease burden, and there is a high unmet clinical need for effective treatment options. This study evaluated the safety and efficacy of spesolimab, a novel anti-interleukin-36 receptor antibody, in patients with PPP. Although the primary efficacy endpoint was not met, spesolimab showed a potential treatment effect with a higher rate of achieving PPP ASI50 compared to placebo, and was well tolerated with no significant safety concerns.

DERMATOLOGY AND THERAPY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

The JAK/STAT signaling pathway: from bench to clinic

Xiaoyi Hu et al.

Summary: The JAK/STAT signaling pathway is a crucial cellular signal transduction pathway, associated with various cancers and autoimmune diseases. Researchers discussed the composition, activation, and regulation of this pathway, as well as its role in diseases.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Review Dermatology

Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments

Magdalena Misiak-Galazka et al.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)

Add to Collection

Letter Dermatology

Long-lasting allergic patch test reactions to dental metal allergens in a patient with palmoplantar pustulosis and pustulotic arthro-osteitis

Maiko Kato et al.

JOURNAL OF DERMATOLOGY (2020)

Add to Collection

Article Rheumatology

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Stanley B. Cohen et al.

RMD OPEN (2020)

Add to Collection

Review Microbiology

JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results

Krzysztof Szalus et al.

MICROORGANISMS (2020)

Add to Collection

Article Dermatology

Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study

Ulrich Mrowietz et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Review Immunology

Emerging Topical and Systemic JAK Inhibitors in Dermatology

Farzan Solimani et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study

J. M. Bae et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Article Dermatology

Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study

F. Valenzuela et al.

BRITISH JOURNAL OF DERMATOLOGY (2018)

Add to Collection

Article Dermatology

Retrospective analysis of the clinical response of palmoplantar pustulosis after dental infection control and dental metal removal

Michiyoshi Kouno et al.

JOURNAL OF DERMATOLOGY (2017)

Add to Collection

Letter Dermatology

Psoriasis and palmoplantar pustulosis: an endless debate?

A. M. G. Brunasso et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)

Add to Collection

Letter Dermatology

Is palmoplantar pustulosis simply a variant of psoriasis or a distinct entity?

M. Misiak-Galazka et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)

Add to Collection

Article Dermatology

Quality of life and comorbidities in palmoplantar pustulosis - a cross-sectional study on 102 patients

H. Trattner et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)

Add to Collection

Article Allergy

Insulin resistance, diabetes mellitus and thyroid dysfunction in patients with palmoplantar pustulosis: a case-controlled study

Hatice Atas et al.

POSTEPY DERMATOLOGII I ALERGOLOGII (2017)

Add to Collection

Letter Dermatology

Treatment of Alopecia Areata With Tofacitinib

Omer Ibrahim et al.

JAMA DERMATOLOGY (2017)

Add to Collection

Review Dermatology

The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review

Isabelle M. Sanchez et al.

DERMATOLOGY AND THERAPY (2017)

Add to Collection

Review Medicine, Research & Experimental

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

John J. O'Shea et al.

ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)

Add to Collection

Article Dermatology

Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial

R. Bissonnette et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)

Add to Collection

Review Dermatology

Management of palmoplantar pustulosis: do we need to change?

U. Mrowietz et al.

BRITISH JOURNAL OF DERMATOLOGY (2011)

Add to Collection

Letter Dermatology

Can we really separate palmoplantar pustulosis from psoriasis?

A. M. G. Brunasso et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2010)

Add to Collection

Article Immunology

IL-8 as antibody therapeutic target in inflammatory diseases: Reduction of clinical activity in palmoplantar pustulosis

Lone Skov et al.

JOURNAL OF IMMUNOLOGY (2008)

Add to Collection

Article Immunology

Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP)

H Nozawa et al.

CLINICAL IMMUNOLOGY (2005)

Add to Collection

Article Rheumatology

Targeting the Jak/STAT pathway for immunosuppression

JJ O'Shea

ANNALS OF THE RHEUMATIC DISEASES (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.